Clinical Trial Update: Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating dexmedetomidine during deep brain stimulation for Parkinson's disease, essential tremor, and dystonia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystonia
• Essential Tremor
• Parkinson Disease

Drugs mentioned

• Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: Vanderbilt University | Conditions: Parkinson's Disease, Essential Tremor | Phase 2, Phase 3 | Status: WITHDRAWN